Latest news with #neuroimaging
The Australian
04-06-2025
- Business
- The Australian
Vital Signs: Compumedics
Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to Gordon Haid, the Global Neuro-Imaging Business Director of Compumedics (ASX:CMP), a medical device company focused on diagnostic tech for sleep, brain and blood flow monitoring. Founded in 1987, Compumedics' strategy was initially focused on developing its core competency, Sleep Diagnostics. The company even set up Australia's first ever fully computerised sleep clinic. Today, Compumedics has evolved into one of the world's leading suppliers of medical technology for sleep, neuro diagnostics and ultrasonic blood flow monitoring, with products distributed to clients around the globe, helping millions of people who suffer from debilitating sleep, neurological and other healthcare problems. This podcast was developed in collaboration with Compumedics, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.
Yahoo
19-05-2025
- Health
- Yahoo
Cortechs.ai and ALZ-NET Announce Strategic Collaboration to Improve Alzheimer's Disease Care Through AI-Driven Imaging
SAN DIEGO, May 19, 2025 /PRNewswire/ -- a global leader in AI-driven neuroimaging solutions, today announced a strategic collaboration with the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) to enhance the quality of care for people living with Alzheimer's disease. This collaboration brings together advanced imaging platform, NeuroQuant® for ARIA, with ALZ-NET's robust real-world data network to help inform clinical decision-making, improve care delivery and contribute to future treatment guidelines. As part of the collaboration, discounted access to NeuroQuant® for ARIA will be offered to ALZ-NET sites across diverse clinical settings. NeuroQuant® for ARIA offers precise segmentation, quantification, and longitudinal tracking of both FLAIR and T2GRE/SWI lesions. This advanced functionality offers assistance with the surveillance of amyloid-related imaging abnormalities, such as ARIA-E and ARIA-H, in patients receiving anti-amyloid therapies. NeuroQuant® for ARIA is validated on both 2D and 3D FLAIR sequences, ensuring compatibility with a broad range of imaging protocols. NeuroQuant® for ARIA is the only clinically validated solution that detects and quantifies cerebral microbleeds and superficial siderosis on both T2GRE and SWI scans. Coupled with FLAIR lesion quantification of cerebral edema, NeuroQuant® for ARIA offers a complete solution for AI-assisted monitoring of Alzheimer's Disease patients on anti-amyloid immunotherapies. Dr. Ana Franceschi, a nationally recognized authority in dementia imaging and molecular neuroimaging and a member of both the Medical Advisory Board and ALZ-NET's Imaging Work Group, expressed strong support for the initiative: "It is a privilege to serve on Medical Advisory Board as we embark on this important collaboration with ALZ-NET. Combining advanced neuroimaging analytics with real-world data is a critical step in optimizing safety and monitoring for Alzheimer's patients receiving anti-amyloid therapies. This collaboration holds great promise for clinicians and patients alike." Sponsored by the Alzheimer's Association® and managed and operated by the American College of Radiology® (ACR®), ALZ-NET is a voluntary health care provider-enrolled network collecting real-world clinical and imaging data from patients evaluated for or treated with new FDA-approved Alzheimer's therapies Through the collection of longitudinal, real-world data across a multi-site network, ALZ-NET aims to provide evidence-based critical insights into long-term safety and efficacy of Alzheimer's therapies.. "Alzheimer's disease is a prevalent and devastating condition that touches millions of families. Our collaboration with ALZ-NET represents a shared commitment to using data and technology to improve how we care for people with dementia," says Kyle Frye, CEO of "With NeuroQuant® for ARIA, we're giving clinicians the tools they need to make smarter, safer decisions, and by connecting with ALZ-NET's powerful data network, we can collectively advance treatment practices for the entire field." For more information about visit and to learn more about or register to participate in ALZ-NET, visit or email About is a leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and early detection, empowering healthcare providers to deliver better outcomes for patients. The company develops and markets innovative medical device software that provides quantitative MR imaging analysis to assist clinicians in assessing neurodegeneration, as well as brain and prostate cancer. industry-leading imaging solutions offer radiologists, oncologists, and urologists a streamlined, cost-effective way to assess brain and prostate health, including cancer evaluation. The company also offers FDA-cleared products for evaluating neurological disorders such as Alzheimer's disease, epilepsy, multiple sclerosis, brain trauma, tumors, and other brain abnormalities. For more information, please visit and follow us on Twitter, LinkedIn, and Facebook. For more information, please contact: info@ +1 858 459 970 View original content to download multimedia: SOURCE
News.com.au
14-05-2025
- Health
- News.com.au
Health Check: Compumedics claims world first ‘kids eat for free' brain scanning breakthrough
Compumedics' MEG unit can scan adult and kid's heads at the same time – a technically tricky task Microba's comprehensive gut testing reveals all is not well in the tummy region Trump's drug pricing blitz should be 'immaterial', says Telix Brain-scanning specialist Compumedics (ASX:CMP) reports a world's first: decent concurrent readings from both adult and children patients imaged by the same MEG device at China's Tianjin Normal University. It's like the old Smorgy's: kids eat for free. MEG stands for magnetoencephalography, a non-invasive neuroimaging technique that maps brain activity by recording magnetic fields produced by electrical currents in the grey matter. The problem to date is that the head scanners on MEGs haven't been compatible with young and adult noggins, which require two separate units. Many MEG measurements are done on kids, especially for epilepsy diagnostics. Compumedics' Orion Lifespan MEGs rectify this this with a two-scanner configuration (the scanner look like old-fashioned hair dryers at a salon). 'A key principle of MEG is that because magnetic fields drop off very rapidly with distance, the sensors should be as close as possible to the sources of the brain signals,' the company says. 'Since the sensors must be within a rigid helmet shape, a child's small head in an adult size helmet results in sensors far from the brain.' Orion Lifespan MEGs also enable better cooling – resulting in more sensitive measurements – and full recycling of the expensive coolant, liquid helium. This enables around-the-clock use of the units. Tianjin Normal University was the first of four Chinese institutions to buy an Orion MEG. In March this year Compumedics sold its fourth unit, to Hangzhou Normal University in a $5.7 million deal. The orders to date account for about $20 million of revenue. Compumedics founder and executive chair Dr David Burton says the company has spent 'many millions' over the last decade to perfect the units. Currently, about 200 MEGs are used globally. Burton reckons eventually there should be just as many MEGs as magnetic resonance imaging units – and there are 34,000 of the latter in use. Microba says we've all had a gutful An expansive study carried out by microbiome specialist Microba Life Sciences (ASX:MAP) suggests our tummies are not in the best of shape, but the ailments can be rectified with better clinical management. The company analysed 4600 patient results from its Metaxplore tests, which scan for 28,000 microbial species in the lower intestine. Some of these bugs are friendly and some of them are pathogenic. In more than 70% of cases, the preliminary results showed abnormalities in gut bacteria, signs of infection or inflammation markers "that could inform targeted treatment strategies". More than 42% of the tests showed microbiome markers linked to gastrointestinal health, while close to 10% exhibited symptoms such as inflammation, pancreatic insufficiency and blood in stools. Microba's selling point is that 65% of patients reported an improvement after following 'clinically directed recommendations informed by Metaxplore". The test can help clinicians to apply "personalised, multi-dimensional treatment plans to support the clinical management of patients with chronic and functional lower gastrointestinal disorders'. Even the tests identifying no problems can be helpful in terms of ruling out causes. In some cases, they may point to 'psychological or neurological contributors' to symptoms. In its March quarter update, Microba reported revenue of $3.4 million, down 14% . But management guided to full-year turnover of $15.25-16.25 million, 26-34% higher. Microba doubled sales of Metaxplore tests during the stanza, to 3225, taking the annualised run rate to 12,900 units. Locally the assays sell for $369 a pop. Telix shrugs off Trump drug pricing threat Telix Pharmaceuticals (ASX:TLX) has declared the Trump administration's proposed move to lower prescription drug prices has a 'a low likelihood of material impact' on the nuclear medicine group's business. The key reason is the unique nature of radiopharmaceuticals, which rely on a complex supply chain and 'just-in-time' manufacturing. In other words: the isotopes used on US patients need to be made in the US because of short half lives. The ready-to-inject radioactive doses are delivered through local nuclear pharmacy distributors. Under its most favoured nation decree, The Trump administration plans to benchmark local drug prices against those charged in the cheapest of the industrialised nations. The Prez claims this will reduce drug prices by up to 80% and save Medicare a poultice of money. But Telix says its localised production makes international pricing comparisons "challenging to benchmark". Telix derives most of its revenue in the US, from its approved prostate cancer imaging agent Illucix. The company intends to go ahead with commercialising kidney and brain cancer imaging products – Zircaix and Pixclara respectively – and advance cancer therapy agents. The company promises 'pharmaco-economically defensible' pricing in the US. Telix's comments were by way of a news item on its website, rather than an ASX announcement. OIL say! – that's a decent share rise Today's biotech winner is Optiscan (ASX:OIL), with its shares bounding three cents – 30% – in initial trade. Optiscan had nothing fresh to report, but yesterday said a robotic surgery development effort with Mayo Clinic was going well. Specifically, the venture is about incorporating Optiscan's digital confocal laser endomicroscopic (CLE) imaging in the robotic system. The robots do the fiddly work, while the surgeons guide via joystick (not even necessarily in the same room). The robots have a steadier hand – and often a better bedside manner. Rather than wait for biopsies, the CLE enables a real-time assessment in terms of cancer cell types and the extent of the margins at the edge of the tumour. 'This capability is expected to streamline surgical workflows, enhance decision-making, and reduce the likelihood of follow-up surgeries,' the company says. Optiscan CEO Dr Camile Farah says the venture – initially aimed at breast surgery – has 'materially progressed'.
Daily Mail
07-05-2025
- Health
- Daily Mail
EXCLUSIVE My breakthrough investigation into sinister 'sonic' brain attacks on Americans reveals damning proof of a Biden White House cover-up, writes CATHERINE HERRIDGE
'I feel like I am disappearing,' a medically retired Defense Department professional told me over a meal near Capitol Hill. Then, she bravely showed me a neuroimaging scan of her brain. It was disturbing. Her mind is wasting away.
